AFP and hepatocellular carcinoma: Approximately 4.2% (28/672), 16.7% (27/162), and 30.6% (15/49) of patients with AFP levels of < 5, 5–9, and > 9 ng/mL, respectively, developed HCC (P < 0.001); the median treatment duration was 42.6 ± 21, 38.1 ± 30, and 20.5 ± 30.2 months for these patients.